PT2611779T - Formas cristalinas de um inibidor do fator xa - Google Patents

Formas cristalinas de um inibidor do fator xa

Info

Publication number
PT2611779T
PT2611779T PT117574673T PT11757467T PT2611779T PT 2611779 T PT2611779 T PT 2611779T PT 117574673 T PT117574673 T PT 117574673T PT 11757467 T PT11757467 T PT 11757467T PT 2611779 T PT2611779 T PT 2611779T
Authority
PT
Portugal
Prior art keywords
inhibitor
factor
crystalline forms
crystalline
forms
Prior art date
Application number
PT117574673T
Other languages
English (en)
Portuguese (pt)
Inventor
Pandey Anjali
R Capodanno Vincent
Corcoran Liam
Mcnevin Michael
Zoraida Arroyo Itzia
M Wenslow Robert
G Ball Richard
L Margelefsky Eric
K Maher Timothy
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of PT2611779T publication Critical patent/PT2611779T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT117574673T 2010-09-01 2011-08-31 Formas cristalinas de um inibidor do fator xa PT2611779T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37933910P 2010-09-01 2010-09-01
US201161454396P 2011-03-18 2011-03-18

Publications (1)

Publication Number Publication Date
PT2611779T true PT2611779T (pt) 2016-11-21

Family

ID=45773260

Family Applications (1)

Application Number Title Priority Date Filing Date
PT117574673T PT2611779T (pt) 2010-09-01 2011-08-31 Formas cristalinas de um inibidor do fator xa

Country Status (13)

Country Link
US (1) US8946269B2 (enExample)
EP (1) EP2611779B1 (enExample)
JP (4) JP2013536864A (enExample)
CN (1) CN103261161B (enExample)
AR (1) AR082804A1 (enExample)
AU (1) AU2011295909B2 (enExample)
CA (1) CA2810004C (enExample)
ES (1) ES2603084T3 (enExample)
IL (1) IL224698A (enExample)
NZ (1) NZ608442A (enExample)
PT (1) PT2611779T (enExample)
TW (1) TW201221128A (enExample)
WO (1) WO2012031017A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8980876B2 (en) 2010-10-28 2015-03-17 The Procter & Gamble Company Inhibition of microbial growth by aconitase inhibition
WO2013033370A1 (en) 2011-08-31 2013-03-07 Portola Pharmaceuticals, Inc. Prevention and treatment of thrombosis in medically ill patients
JP6227878B2 (ja) * 2012-03-16 2017-11-08 ラクステラ・インコーポレイテッドＬｕｘｔｅｒａ，Ｉｎｃ． 光インターポーザのための方法及びシステム
US9200268B2 (en) 2012-12-27 2015-12-01 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
US20140346397A1 (en) 2012-12-27 2014-11-27 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
CN104693114B (zh) * 2013-12-10 2019-08-16 四川海思科制药有限公司 一种贝曲西班的改进的制备方法
CN105085387A (zh) * 2014-05-20 2015-11-25 四川海思科制药有限公司 贝曲西班盐及其制备方法和用途
WO2017091757A1 (en) 2015-11-24 2017-06-01 Portola Pharmaceuticals, Inc. Isotopically enriched betrixaban
CN106995405A (zh) * 2016-01-25 2017-08-01 重庆医药工业研究院有限责任公司 一种贝曲西班马来酸盐无定型物及其制备方法
US20190300483A1 (en) * 2016-06-02 2019-10-03 Dr. Reddy's Laboratories Limited POLYMORPHS OF BETRlXABAN & ITS MALEATE SALT
EP3254674A1 (en) 2016-06-08 2017-12-13 Sandoz Ag Pharmaceutical compositions of betrixaban maleate
EP3293174A1 (en) 2016-09-09 2018-03-14 Sandoz Ag Crystalline salts of betrixaban
WO2018069936A1 (en) 2016-10-13 2018-04-19 Mylan Laboratories Limited Polymorphs and solid dispersion of betrixaban and methods for the preparation thereof
CN107382897B (zh) * 2017-07-10 2021-05-04 浙江宏元药业股份有限公司 一种贝曲西班的中间体及其制备方法和应用
EP3510996A1 (en) * 2018-01-11 2019-07-17 Sandoz AG Pharmaceutical compositions of betrixaban
CN108570003A (zh) * 2018-06-01 2018-09-25 浙江宏元药业股份有限公司 一种贝曲西班马来酸盐的一水无定形及其制备方法
CN113905715B (zh) 2019-06-28 2025-04-15 宝洁公司 光增强处理方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9226238D0 (en) 1992-12-16 1993-02-10 Scherer Ltd R P Encapsulation apparatus and process
US6140351A (en) 1997-12-19 2000-10-31 Berlex Laboratories, Inc. Ortho-anthranilamide derivatives as anti-coagulants
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
MXPA02006660A (es) * 2000-01-07 2002-12-13 Transform Pharmaceuticals Inc Formacion, identificacion y analisis de diversas formas solidas de alto rendimiento.
AU2001245353A1 (en) 2000-02-29 2001-09-12 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
US6627646B2 (en) 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
DE10322469A1 (de) 2003-05-19 2004-12-16 Bayer Healthcare Ag Heterocyclische Verbindungen
US7696352B2 (en) 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
CN1968922A (zh) 2004-06-18 2007-05-23 米伦纽姆医药公司 因子xa抑制剂
KR101358574B1 (ko) * 2005-11-08 2014-02-04 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｘａ 인자 억제제, ｎ­（5­클로로­2­피리디닐）­2­［［4­［（디메틸아미노）이미노메틸］벤조일］아미노］­5­메톡시­벤자마이드의 약제학적 염 및 다형체
TW200813017A (en) 2006-05-05 2008-03-16 Millennium Pharm Inc Factor XA inhibitors
US20080051578A1 (en) 2006-08-24 2008-02-28 Georg Dahmann Substituted biaryls, process for their manufacture and use thereof as medicaments
PT2404906E (pt) 2006-11-02 2015-11-02 Millennium Pharm Inc Métodos de sintetizar sais farmacêuticos de um inibidor de fator xa
CA2913963A1 (en) 2006-12-08 2008-06-19 Millenium Pharmaceuticals, Inc. Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor
EP2114930A2 (en) 2007-01-05 2009-11-11 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
AU2008239659B2 (en) 2007-04-13 2013-09-05 Millennium Pharmaceuticals, Inc. Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor
EP2586439A1 (en) * 2007-05-02 2013-05-01 Portola Pharmaceuticals, Inc. Combination therapy with a compound acting as a platelet ADP receptor inhibitor
SI2915564T1 (sl) 2007-09-28 2021-03-31 Alexion Pharmaceuticals, Inc. Antidoti za zaviralce dejavnika Ksa in postopki njihove uporabe
US8455439B2 (en) * 2008-11-14 2013-06-04 Portola Pharmaceuticals, Inc. Antidotes for factor Xa inhibitors and methods of using the same in combination with blood coagulating agents
JP5766204B2 (ja) 2009-12-17 2015-08-19 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 第Ｘａ因子阻害剤の合成方法
AR082803A1 (es) 2010-09-01 2013-01-09 Portola Pharm Inc Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p

Also Published As

Publication number Publication date
WO2012031017A1 (en) 2012-03-08
AR082804A1 (es) 2013-01-09
CA2810004C (en) 2019-09-10
CA2810004A1 (en) 2012-03-08
AU2011295909B2 (en) 2015-05-21
JP2015232046A (ja) 2015-12-24
ES2603084T3 (es) 2017-02-23
EP2611779A1 (en) 2013-07-10
AU2011295909A1 (en) 2013-04-04
JP2013536864A (ja) 2013-09-26
NZ608442A (en) 2015-04-24
CN103261161A (zh) 2013-08-21
CN103261161B (zh) 2016-04-27
US8946269B2 (en) 2015-02-03
JP2018024709A (ja) 2018-02-15
TW201221128A (en) 2012-06-01
EP2611779B1 (en) 2016-08-10
JP2019135258A (ja) 2019-08-15
IL224698A (en) 2017-01-31
US20120071519A1 (en) 2012-03-22

Similar Documents

Publication Publication Date Title
PT2611779T (pt) Formas cristalinas de um inibidor do fator xa
ZA201301802B (en) Besylate salt of a btk inhibitor
SG10201500451TA (en) Crystalline forms of a purine derivative
IL223205B (en) Crystal form of benzylbenzene inhibitor 2sglt
IL209196A0 (en) A crystalline form of posaconazole
PT2576505T (pt) Processo para a preparação de pleuromutilinas
ZA201503238B (en) Crystalline forms of a factor xia inhibitor
IL221198A0 (en) Crystalline salts of a potent hcv inhibitor
PL2453894T3 (pl) Postać krystaliczna wolnej zasady związku bifenylowego
PL2578595T3 (pl) Krystaliczna lewoizowalerylospiramycyna I
SG10201501226VA (en) New crystalline form of a cyclopropyl benzamide derivative
ZA201300154B (en) Crystalline form of a 3-phenoxymethylpyrrolidine compound
ZA201104319B (en) Crystalline forms of a 3-carboxypropyl-aminotetralin compound
PL2407612T3 (pl) Zastosowanie skrzynki zbrojenia
TWM390210U (en) Improved structure of a tool holder
TWM390844U (en) Structure improvement of a screwdriver
HK1186063A (en) Besylate salt of a btk inhibitor
GB201004308D0 (en) New inhibitor compounds
TWM385440U (en) Structure improvement of a screwdriver
HK1178531A (zh) 环丙基苯甲酰胺衍生物的新结晶形式
TWM402641U (en) Structure of a place box